Progressive central vision loss as a result of macular damage is a condition that causes.

The rationale behind the use of rheopheresis is that it accompanies the development of the ICH risk factors (such as fibrinogen, LDL, fibronectin, vWF high molecular weight molecules) from patient plasma removal of blood viscosity. As a consequence of this, blood viscosity and decreased platelet aggregation and erythrocyte membrane results in increased elasticity. This results in increased retinal pigment improves perfusion of the epithelium, reduces hypoxia and allows recovery of retinal pigment epithelium function

Reoferez

0.8-1.2 TPH

1 or 2 times a week

Albumin when needed, TDP, HES

8-10 procedures, 2 procedures per week for a period of 8-21 weeks or 2 procedures in the first week followed by 1 per week for 8 weeks a total of 10 operations